Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in Locally Advanced NSCLC Patients

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 7, 2022

Primary Completion Date

July 7, 2025

Study Completion Date

July 7, 2026

Conditions

Non-small Cell Lung CancerConsolidation ImmunotherapyRadiotherapy or Sequential Chemoradiation

Interventions

DRUG

Tislelizumab

Tislelizumab: 200mg d1,q21d\*17

Trial Locations (1)

RECRUITING

Peking University Cancer Hospital and Institute, Beijing

All Listed Sponsors

lead

Peking University Cancer Hospital & Institute

OTHER